Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retrospective single instituttion study to describe the frequency and spectrum of cutaneous adverse events in patients with various types of cancer taking anti-PD-1 therapy

Next Previous
Trial Profile

Retrospective single instituttion study to describe the frequency and spectrum of cutaneous adverse events in patients with various types of cancer taking anti-PD-1 therapy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer; Head and neck cancer; Hodgkin's disease; Kidney-neoplasms; Malignant melanoma; Non-small cell lung cancer
  • Focus Adverse reactions

Most Recent Events

  • 09 Jul 2019 New trial record
  • 08 Jul 2019 Results published in the Journal of Korean Medical Science

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top